<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767714</url>
  </required_header>
  <id_info>
    <org_study_id>EFC12482</org_study_id>
    <secondary_id>MOZ14409</secondary_id>
    <secondary_id>U1111-1131-0145</secondary_id>
    <nct_id>NCT01767714</nct_id>
  </id_info>
  <brief_title>Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of Plerixafor (0.24 mg/kg) Plus G CSF (10 µg/kg) Versus G CSF (10 µg/kg) Plus Placebo to Mobilize and Collect ≥5 × 106 CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to determine if NHL patients mobilized with G-CSF (10 µg/kg/day [GRAN® only])
      plus 0.24 mg/kg/day of plerixafor are more likely to achieve a target number of ≥5 × 10^6
      CD34+ cells/kg in 4 or fewer days of apheresis than NHL patients mobilized with G-CSF plus
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients who are unable to achieve adequate apheresis cell counts may enter an
      Open-Label Rescue Period where they will receive plerixafor, following the same study
      schedule as during the Double-Blind Treatment Period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who meet the target of ≥5 × 10^6 CD34+ cells/kg in 4 or fewer days of apheresis</measure>
    <time_frame>Days 5- Day8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who achieve ≥2 × 10^6 CD34+ cells/kg within 4 or fewer days of apheresis</measure>
    <time_frame>Day 5 - Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of apheresis to collect ≥2 × 10^6 CD34+ cells/kg</measure>
    <time_frame>Up to achieve the target of collecting ≥2 × 10^6 CD34+ cells/kg</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of apheresis to collect ≥5 × 10^6 CD34+ cells/kg</measure>
    <time_frame>Up to achieve the target of collecting ≥5 × 10^6 CD34+ cells/kg</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of CD34+ cells collected</measure>
    <time_frame>Day 5 - Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from transplantation to neutrophil and platelet (PLT) engraftment</measure>
    <time_frame>up to 30 days post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)</measure>
    <time_frame>from signed Informed Consent Form (ICF) to 30 days post-transplant and then ongoing as needed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 4 - Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>Day 4 - Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve 0 to 10 hours post-dose (AUC0-10)</measure>
    <time_frame>Day 4 - Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve 0 to last observed concentration (AUClast)</measure>
    <time_frame>Day 4 - Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>Day 4 - Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of extrapolation of AUC (AUCext)</measure>
    <time_frame>Day 4 - Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T1/2)</measure>
    <time_frame>Day 4 - Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>Day 4 - Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CL/F)</measure>
    <time_frame>Day 4 - Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood CD34+ cell counts (Pharmacodynamic analysis)</measure>
    <time_frame>Day 4 - Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The fold-increase in the number of circulating CD34+ following the first dose of plerixafor or placebo, with the first apheresis day (Day 5) value serving as the primary estimate</measure>
    <time_frame>Day 5 - Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>G-CSF + plerixafor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive plerixafor in the evening up to a maximum of 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-CSF + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive placebo in the evening up to a maximum of 4 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte-colony stimulating factor (G-CSF)</intervention_name>
    <description>10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection</description>
    <arm_group_label>G-CSF + plerixafor</arm_group_label>
    <arm_group_label>G-CSF + Placebo</arm_group_label>
    <other_name>GRAN®, Filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>0.24 mg/kg/day subcutaneous injection</description>
    <arm_group_label>G-CSF + plerixafor</arm_group_label>
    <other_name>Mozobil, AMD3100, GZ316455</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection</description>
    <arm_group_label>G-CSF + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a biopsy-confirmed diagnosis of NHL

          -  Is in first or second complete remission or partial remission, defined for the purpose
             of this study as complete or partial response following first- or second-line therapy

          -  Treatment with an autologous peripheral HSC transplant is planned and the patient is
             eligible for autologous transplantation

          -  Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Has recovered from all acute toxic effects of prior chemotherapy or other cancer
             treatment.

          -  Has an actual body weight &lt;175% of their ideal body weight (IBW)

          -  The patient agrees to use a highly effective method of contraception from Day 1
             through ≥3 months following plerixafor treatment.

        Exclusion Criteria:

          -  Concurrent serious illness and pathological conditions

          -  Has undergone previous HSC collections or collection attempt

          -  Has had any autologous or allogeneic HSC transplant

          -  Has active central nervous system (CNS) involvement

          -  Bone marrow lymphoma cells involvement &gt;20%, as assessed by bone marrow biopsy within
             4 months before signing the ICF

          -  Has received radiation therapy to the pelvis

          -  Has a diagnosis of all leukemias including any type of CLL

          -  Active infection

          -  Pregnant or nursing

          -  Anticipated post-transplant chemotherapy and/or radiation therapy below the diaphragm

          -  Received any prior radio-immunotherapy

          -  Prior 1,3-bis(2-chloroethyl)-1-nitroso-urea (BCNU) within 6 weeks prior to first dose
             of G-CSF

          -  Prior cancer therapy, other investigational therapy within 4 weeks prior to first dose
             of G-CSF

          -  Prior granulocyte/macrophage-colony stimulating factor (GM-CSF) or pegfilgrastim
             within 3 weeks prior to the first dose of G-CSF

          -  Prior G-CSF within 2 weeks prior to the first dose of G-CSF

          -  Inadequate organ funtion evidenced by unacceptable laboratory result
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 156017</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156001</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156005</name>
      <address>
        <city>Beijing</city>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156002</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156003</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156020</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156016</name>
      <address>
        <city>Fuzhou</city>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156021</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156011</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156018</name>
      <address>
        <city>Nanjing</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156009</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156010</name>
      <address>
        <city>Suzhou</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156008</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156013</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156015</name>
      <address>
        <city>Xi'An</city>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156022</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2013</study_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

